Drug Development Consulting: Pre-Clinical to Regulatory Submission
Independent regulatory advisory for the full drug development lifecycle — from early-stage strategy through clinical phases to EU marketing authorisation or North American approval.
Care Europe provides independent regulatory consulting throughout the drug development lifecycle: pre-clinical strategy, clinical trial design support, dossier preparation, and regulatory submission for chemical, herbal/botanical, biological, and OTC medicinal products in the EU, USA, and Canada.
Drug development is a long, complex, and high-stakes process. Regulatory mistakes made at the pre-clinical stage can invalidate studies, delay programmes, and cost millions. Care Europe provides independent regulatory consulting throughout the development lifecycle — helping pharmaceutical companies, biotech startups, and herbal medicine developers navigate EU, FDA, and Health Canada requirements at every stage, from initial product strategy through to first marketing authorisation.
Pre-Clinical Regulatory Strategy
Regulatory strategy must be defined before pre-clinical studies begin. The wrong study design, inappropriate models, or inadequate documentation can render pre-clinical data unusable for regulatory submission. Care Europe reviews your development programme against the relevant EU regulatory guidelines (EMA guidelines, ICH guidelines, HMPC monographs for herbal products) and advises on study design, data package requirements, and the scientific advice process. For herbal and botanical medicinal products, we assess eligibility for the Traditional Use registration route (Directive 2004/24/EC) as an alternative to full marketing authorisation.
Clinical Advisory and Dossier Preparation
The clinical development plan must be designed to support the intended indication and target market. Care Europe advises on clinical trial design, protocol requirements, and the data package needed for EU marketing authorisation applications (MAA). We help prepare the clinical sections of the Common Technical Document (CTD) format required for EU and ICH-compliant submissions. For OTC switches and line extensions, we identify the applicable procedure and data requirements. For Health Canada submissions, we align clinical evidence with the Health Canada New Drug Submission (NDS) or Abbreviated NDS requirements.
Regulatory Submission and Authority Interaction
Preparing and submitting a marketing authorisation application requires deep knowledge of both the technical requirements and the procedural expectations of regulatory authorities. Care Europe compiles and reviews CTD dossiers, prepares responses to regulatory questions (LoQ/LoOI), and supports scientific advice meetings with EMA, national competent authorities, FDA, or Health Canada. We manage the submission process and coordinate with clinical, quality, and non-clinical teams to ensure dossier completeness before submission.
Services & Methods Included
- ✓ Pre-clinical regulatory strategy and study design advice
- ✓ ICH guideline compliance review (M3, S1–S9, E series)
- ✓ Clinical trial protocol regulatory review
- ✓ Common Technical Document (CTD) preparation
- ✓ Traditional herbal registration route (Directive 2004/24/EC) assessment
- ✓ EMA/FDA scientific advice meeting preparation
- ✓ Marketing authorisation application (MAA) compilation
- ✓ Response to LoQ / LoOI (regulatory authority questions)
- ✓ OTC switch regulatory strategy
- ✓ Health Canada NDS/ANDS submission support
Regulatory Standards & Compliance
- EU Directive 2001/83/EC
- EU Directive 2004/24/EC (Herbal)
- ICH M4 CTD Format
- ICH E6 (GCP)
- ICH M3 (Non-clinical Safety Studies)
- EMA Scientific Guidelines
- FDA 21 CFR Parts 312/314
- Health Canada NDS/ANDS Requirements
Industries We Serve
- Pharmaceutical Companies
- Herbal & Botanical Medicine Developers
- Biotech Startups
- OTC Drug Manufacturers
- Contract Research Organisations (CROs)
- University Spin-Outs
Request a Consultation
Tell us about your product and regulatory challenge. We'll respond within 24 hours with an honest assessment and clear next step.
Get a Free Assessment →Frequently Asked Questions
What is the Traditional Herbal Medicinal Product (THMP) registration route?
The Traditional Herbal Medicinal Products Directive (2004/24/EC) created a simplified registration route for herbal medicines with at least 30 years of traditional use (including 15 years in the EU). Products approved under this route do not require full clinical trials — they rely on traditional use evidence. Care Europe assesses whether your herbal product qualifies for THMP registration and manages the entire dossier preparation and submission process.
At what stage should I involve a regulatory consultant in drug development?
As early as possible. Ideally, regulatory strategy should be defined before pre-clinical studies begin to ensure study designs are fit for purpose. Early regulatory input prevents costly study repeats. Care Europe offers pre-IND/pre-CTA strategic reviews to align your development programme with regulatory expectations before significant investment is made.
Can you help with both EU and North American submissions for the same product?
Yes. Care Europe has expertise in both EU (EMA/national authorities) and North American (FDA, Health Canada) regulatory frameworks. We provide parallel strategy that maximises data leverage across jurisdictions and identifies where EU and NA data packages align or diverge. This is particularly valuable for companies targeting simultaneous global market entry.
Why brands choose Care Europe for drug development consulting
Registered in France
EU regulatory partner with legal standing
Bilingual EN/FR
Reports in English and French
NA–EU Bridge
We understand both regulatory worlds
Ready to start your EU drug development consulting?
Tell us about your product and target EU markets. We'll respond within 24 hours with a regulatory assessment and next steps.
Get a Regulatory Quote →